# A Study of Cardiovascular Events iN Diabetes Plus

Study · id `cardio:ct-nct05441267` · Cardiovascular Atlas · release `a25293eeae6350fb` (public)

> General information from published sources, not medical advice, and not reviewed by clinicians. Check the cited source before relying on anything here. Sponsors do not influence what this atlas says.

The atlas's own text and curation may be reused under Creative Commons Attribution-NonCommercial 4.0 International (CC BY-NC 4.0, https://creativecommons.org/licenses/by-nc/4.0/): credit the atlas, and do not use it commercially without a licence from the owner. See the atlas About page. Text quoted from a source stays under that source's own terms, given as the source's reuse\_basis. The atlas's reuse terms do not cover it. The downloads list each quotation with its source in third\_party\_quotations.

**Registry record.** Assembled by a program from [ClinicalTrials.gov record NCT05441267](<https://clinicaltrials.gov/study/NCT05441267>), retrieved 26 October 2026. No person wrote or checked this page.

Also called: NCT05441267

Browse, organ or system: Metabolism  
Browse, condition area: Diabetes and metabolic disease  

## In plain language

A phase 4 trial registered on ClinicalTrials.gov. The registry status is active, not recruiting. It enrolled 21296 participants.

## Technical summary

Registry record NCT05441267. Randomized; quadruple masking; primary purpose prevention. Start 2023-03-13 (actual); primary completion 2028-08-17 (anticipated). Results not posted.

## Key facts

- Design: Interventional study; randomized; quadruple masking; primary purpose prevention
- Phase: Phase 4
- Enrolled: 21296 participants (enrolled count; ClinicalTrials.gov record NCT05441267, source copy `cardio:ctgov-nct05441267-2026-06-23`, retrieved 2026-10-26)
- Started: 2023-03-13 (actual) (ClinicalTrials.gov record NCT05441267, source copy `cardio:ctgov-nct05441267-2026-06-23`, retrieved 2026-10-26)
- Primary completion: 2028-08-17 (anticipated) (ClinicalTrials.gov record NCT05441267, source copy `cardio:ctgov-nct05441267-2026-06-23`, retrieved 2026-10-26)
- Completion: 2048-08-17 (anticipated) (ClinicalTrials.gov record NCT05441267, source copy `cardio:ctgov-nct05441267-2026-06-23`, retrieved 2026-10-26)
- Countries: United Kingdom (ClinicalTrials.gov record NCT05441267, source copy `cardio:ctgov-nct05441267-2026-06-23`, retrieved 2026-10-26)
- Care setting: Not reported
- Registry status: "ACTIVE\_NOT\_RECRUITING" (U.S. National Library of Medicine (ClinicalTrials.gov), source copy `cardio:ctgov-nct05441267-2026-06-23`, retrieved 2026-10-26)

## The registry's words

- Brief title: A Study of Cardiovascular Events iN Diabetes Plus
- Acronym: ASCEND PLUS
- Condition: Diabetes Mellitus, Type 2
- Intervention (Drug): Semaglutide Oral Tablet
- Intervention (Drug): Placebo oral tablet
- Lead sponsor: University of Oxford
- Lead sponsor class: OTHER
- Collaborator: Novo Nordisk A/S
- Collaborator class: INDUSTRY

## Connected pages

- Registry condition terms include this condition: Type 2 diabetes (`cardio:type-2-diabetes`)
- Registry condition terms include this condition: Diabetes mellitus (`core:diabetes-mellitus`)
- Registry intervention name matches this record once doses, forms and salt words are removed: Semaglutide (`cardio:semaglutide`)
- Registry intervention is a member of this class by a sourced record link: GLP-1 receptor agonists (drug class) (`cardio:glp1-receptor-agonists`)
- Registry lists this organization as the lead sponsor: University of Oxford (`cardio:org-university-of-oxford`)
- Registry lists this organization as a collaborator: Novo Nordisk (`cardio:novo-nordisk`)

## Provenance

Content hash: 00d3819a2afca3b1d305e305312598e0275d13de25f39eccd555fa9565cce846
Last substantive edit: 2026-11-08
Evidence last checked: Not recorded
